<DOC>
	<DOC>NCT01618877</DOC>
	<brief_summary>The part B of N01362 is to assess the pharmacokinetic profile of Levetiracetam 1500 mg intravenous (iv) infusion during repeated dosing in Chinese healthy volunteers.</brief_summary>
	<brief_title>A Randomized, Double-blind, Pharmacokinetics Study to Assess Safety, Tolerability of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of Bid Dosing in Chinese Healthy Volunteers</brief_title>
	<detailed_description>The study includes 2 parts, part A is to evaluate the bioequivalence of Levetiracetam (LEV) 1500 mg intravenous (iv) infusion when compared to oral tablet, part B is to assess the pharmacokinetic profile of LEV infusion during repeated dosing in Chinese healthy volunteers.</detailed_description>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Chinese, age 1840, weight â‰¥ 50 kg Healthy volunteers with normal vital signs, good physical and mental health status and normal electrocardiogram and laboratory test History or presence of each systems disorders capable of altering the absorption, metabolism or elimination of drugs, or of constituting a risk factor when taking the study medication History or presence of drug addiction or excessive use of alcohol Symptomatic or asymptomatic Orthostatic Hypotension at screening Current smokers and former smokers Heavy caffeine drinker History of frequent and severe headache Any drug treatment Subjects who are known to have Serum Hepatitis or who are carriers of the Hepatitis B surface antigen, or Hepatitis C antibody or who are HIV positive Subjects on a controlled sodium diet Subject has made a blood donation or had a comparable blood loss</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Keppra Levetiracetam intravenous</keyword>
	<keyword>Multiple dose</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Chinese healthy volunteers</keyword>
</DOC>